Cutaneous toxicities associated with vemurafenib therapy in 107 patients withBRAFV600E mutation-positive metastatic melanoma, including recognition and management of rare presentations
- 11 October 2015
- journal article
- research article
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 173 (4), 1024-1031
- https://doi.org/10.1111/bjd.13958
Abstract
Vemurafenib significantly improved overall survival compared with dacarbazine in patients with metastatic or unresectable BRAF V600E-positive melanoma in the BRIM-3 trial. However, vemurafenib was associated with a number of skin-related adverse events (AEs). To investigate the incidence and management of vemurafenib-associated skin AEs. This retrospective, observational study included adult patients with stage IIIC or IV melanoma who received vemurafenib between March 2010 and August 2013. Patients received oral vemurafenib 960 mg twice daily, with dose interruptions and reductions allowed for AE management. In total 107 patients were treated with vemurafenib during the study period. The most frequent clinically important skin-related AEs were rash (64%), squamoproliferative growths (41%), photosensitivity (40%) and squamous cell carcinoma (SCC) or keratoacanthoma (KA; 20%). Rare cases of granulomatous dermatitis and cutaneous T-cell lymphoma were also found. Rash was manageable with corticosteroids and dose modifications; squamoproliferative growths and SCCs/KAs were treated with cryotherapy and surgical excision, respectively. Patients were counselled regarding phototoxicity. The uncontrolled nature and retrospective design of the study, and the small patient numbers are limitations. Vemurafenib appears to have a predictable and manageable AE profile. Proactive management can limit the impact of AEs on patients, allowing treatment to continue despite toxicities.Funding Information
- Succinct Medical Communications
- Roche Products Ltd
This publication has 25 references indexed in Scilit:
- Cutaneous Granulomatous Eruption and Successful Response to Potent Topical Steroids in Patients Undergoing Targeted BRAF Inhibitor Treatment for Metastatic MelanomaJAMA Dermatology, 2014
- Vemurafenib in patients with BRAFV600 mutated metastatic melanoma: an open-label, multicentre, safety studyThe Lancet Oncology, 2014
- Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label studyThe Lancet Oncology, 2014
- Sarcoidosis associated with vemurafenibBritish Journal of Dermatology, 2013
- Analysis of Dermatologic Events in Vemurafenib-Treated Patients With MelanomaThe Oncologist, 2013
- Frequency and Spectrum of BRAF Mutations in a Retrospective, Single-Institution Study of 1112 Cases of MelanomaThe Journal of Molecular Diagnostics, 2013
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E MutationThe New England Journal of Medicine, 2011
- Distinct Sets of Genetic Alterations in MelanomaThe New England Journal of Medicine, 2005
- Mutations of the BRAF gene in human cancerNature, 2002
- The interstitial granulomatous drug reaction: a distinctive clinical and pathological entityJournal of Cutaneous Pathology, 1998